PTI-1 (SGT-48) is an indole-based synthetic cannabinoid.[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-2. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.[2][3][4]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C21H29N3S |
Molar mass | 355.54 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ "PTI-1". Cayman Chemical. Retrieved 8 July 2015.
- ^ US 7700634, Adam-Worrall J, Morrison AJ, Wishart G, Kiyoi T, McArthur DR, "(Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor.", issued 20 April 2010, assigned to Organon NV
- ^ US 7763732, Paul David Ratcliffe PD, Adam-Worrall J, Morrison AJ, Francis SJ, Kiyoi T, "Indole Derivatives", issued 27 July 2010, assigned to Organon NV
- ^ Kiyoi T, Adam JM, Clark JK, Davies K, Easson AM, Edwards D, et al. (March 2011). "Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists". Bioorganic & Medicinal Chemistry Letters. 21 (6): 1748–53. doi:10.1016/j.bmcl.2011.01.082. PMID 21316962.